Coosemans A, Vergote I, Van Gool S W
Department of Oncology, KU Leuven, Laboratory of Pediatric Immunology, Onderwijs and Navorsing 1, Herestraat 49, box 811, 3000 Leuven, Belgium.
Expert Rev Clin Immunol. 2014 Jun;10(6):705-11. doi: 10.1586/1744666X.2014.910119. Epub 2014 May 2.
Pelvic gynecological malignancies account for 6% of all cancers. In the relapsed state, classical treatments are limited. There is an urgent need for new and personalized treatment. Wilms' tumor gene 1 (WT1) is the most important tumor-associated antigen. Although highly present in gynecological tumors, active immunotherapy against it is still underexplored. This review gives an insight into the importance of WT1 in pelvic gynecological malignancies and the first taken steps into the world of WT1 immunotherapy.
盆腔妇科恶性肿瘤占所有癌症的6%。在复发状态下，传统治疗方法有限。迫切需要新的个性化治疗方法。威尔姆斯瘤基因1（WT1）是最重要的肿瘤相关抗原。尽管在妇科肿瘤中高度存在，但针对它的主动免疫疗法仍未得到充分探索。这篇综述深入探讨了WT1在盆腔妇科恶性肿瘤中的重要性以及WT1免疫疗法领域迈出的第一步。
